Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)



Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Paris, France, June 29, 2022 – 6:00 p.m. CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specialized in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces that the European Patent Office (EPO) has granted a new patent that strengthens Acticor Biotech’s patent portfolio. It provides protection for the use of glenzocimab in thrombotic diseases in Europe until 2036.

Read More »

Latest Insights

Launch of Vik Colorectal in Spain

We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!


Archamps, 3rd June 2019 – TransCure bioServices (France), a one-stop-shop preclinical services company dedicated to in-vivo full human immune system mouse models, today announced

Incepto lauches its AI solution

Incepto is the European platform for applied AI: unified, secure and seamlessly integrated into your clinical workflows and your workstations (RIS/PACS/Viewer).